Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (351-360 of 512) with videos related to

Pageof 52
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 30, 2021
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapyIthar Gataa, Laura Mezquita, Caroline Rossoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Cancer Cell|July 1, 2021
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemicArnaud Bayle, Capucine Baldini, Patricia Martin-Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II TrialAlexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
European Radiology|April 24, 2020
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaAlison Dormieux, Laura Mezquita, Paul Henry Cournede, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
Biomarker Research|December 13, 2019
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, et al.
Pageof 52

Showing results (351-360 of 512) with videos related to

Sort By:
Pageof 52
European Journal of Cancer (Oxford, England : 1990)|January 30, 2021
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapyIthar Gataa, Laura Mezquita, Caroline Rossoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Cancer Cell|July 1, 2021
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemicArnaud Bayle, Capucine Baldini, Patricia Martin-Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II TrialAlexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
European Radiology|April 24, 2020
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaAlison Dormieux, Laura Mezquita, Paul Henry Cournede, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
Biomarker Research|December 13, 2019
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, et al.
Pageof 52